4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

960.00p
   
  • Change Today:
      10.00p
  • 52 Week High: 1,000.00
  • 52 Week Low: 500.00
  • Currency: UK Pounds
  • Shares Issued: 12.81m
  • Volume: 6,794
  • Market Cap: £122.93m

4basebio inks development deal with Heqet Therapeutics

By Josh White

Date: Wednesday 27 Apr 2022

LONDON (ShareCast) - (Sharecast News) - Life sciences company 4basebio announced a joint development agreement with Heqet Therapeutics on Wednesday.

The AIM-traded firm said the agreement would be focussed on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration, and the treatment of myocardial infarction more broadly.

Heqet recently closed an €8m (£6.74m) financing round to progress its development programmes.

It was using its proprietary intellectual property to develop therapies enabling heart regeneration and renewal, thus avoiding scar formation on the heart after a myocardial infarction.

Such scarring could eventually lead to cardiac dysfunction and failure, despite improvements in medical interventions.

Under the agreement, the two companies would evaluate the use of 4basebio's 'Hermes' non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte regeneration.

The successful outcome of the project could lead to the proof-of-concept development of a therapy enabling heart regeneration post infarction.

"We are delighted to be working with Heqet on this novel therapy approach for heart repair following myocardial infarction," said chief executive and chief scientific officer Dr Heikki Lanckriet.

"This further demonstrates the flexible application of our Hermes targeted delivery technology within the cell and gene therapy markets."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 960.00p
Change Today 10.00p
% Change 1.05 %
52 Week High 1,000.00
52 Week Low 500.00
Volume 6,794
Shares Issued 12.81m
Market Cap £122.93m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
69.05% below the market average69.05% below the market average69.05% below the market average69.05% below the market average69.05% below the market average
29.63% below the sector average29.63% below the sector average29.63% below the sector average29.63% below the sector average29.63% below the sector average
Price Trend
96.11% above the market average96.11% above the market average96.11% above the market average96.11% above the market average96.11% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
35.65% below the market average35.65% below the market average35.65% below the market average35.65% below the market average35.65% below the market average
40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average

4basebio Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 1,800 @ 960.00p
16:35 1,800 @ 960.00p
16:02 10 @ 959.00p
14:09 77 @ 955.00p
11:04 1,500 @ 931.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page